- Nivestim(TM), Hospira's filgrastim, has received approval from the European Commission (EC) for the prevention of febrile neutropenia (FN) and reduction in duration of chemotherapy-induced ...
MELBOURNE, Australia, Sept. 26 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that it ...
June 17, 2010 — The European Commission has approved a biosimilar formulation for filgrastim (Nivestim; Hospira, Inc; reference product: Neupogen; Amgen, Inc) to prevent febrile neutropenia and reduce ...
"Approval of Nivestim, the first biosimilar filgrastim in Australia, is another important milestone for Hospira as we build our global biosimilars portfolio," said Tim Oldham, president, Asia Pacific, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback